Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC
NCT04157140
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
48
Enrollment
OTHER
Sponsor class
Conditions
Hepatocellular Carcinoma
Interventions
DRUG:
Anlotinib
DEVICE:
TACE+RFA
Sponsor
Jinglong Chen